ArticleCase reports in oncology
"Attenuated" Pulmonary Tumor Thrombotic Microangiopathy on Anti-Vascular Endothelial Growth Factor Treatment: A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary tumor thrombotic microangiopathy associated with prostate cancer achieving over 10-year survival: a case report.International cancer conference journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy (PTTM) is challenging because of rapidly worsening respiratory failure. Vascular endothelial growth factor (VEGF) is involved in PTTM pathogenesis; however, the clinical picture of PTTM in patients with cancer receiving anti-VEGF treatment is unknown. Case Presentation: A 40-year-old man with advanced gastric adenocarcinoma on paclitaxel plus ramucirumab developed a dry cough and, after 2 months of a stable period, dyspnea on exertion. Chest computed tomography (CT) showed bilateral diffuse patchy ground-glass opacities (GGOs). Transbronchial biopsy revealed alveolar hemorrhage and small pulmonary arteries occluded with fibrocellular intimal proliferation, but no tumor cells. Suspecting chemotherapy-induced lung injury, we discontinued the chemotherapy and monitored him carefully without treatment. However, his dyspnea worsened, and follow-up chest CT showed worsening GGOs and right atrial and pulmonary arterial dilatation. Ultrasound cardiography indicated reduced right ventricular function. Lung perfusion scintigraphy confirmed numerous bilateral defects. Right heart catheterization revealed pulmonary hypertension, but no tumor cells on pulmonary wedge aspiration cytology. We clinically diagnosed the patient with PTTM. Three weeks after his initial visit for dyspnea, he was started on nivolumab. One week after treatment, he required home oxygen therapy at 1 L/min on exertion. After two doses of nivolumab, he no longer had dyspnea and discontinued oxygen therapy. Follow-up ultrasound cardiography showed normal pulmonary arterial pressure, and almost all GGOs on chest CT were resolved. Conclusion: VEGF inhibitors may attenuate PTTM symptoms. Even with mild respiratory symptoms, oncologists should consider PTTM in patients with cancer on VEGF inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.